# TRT for ES-SCLC After First Line Treatment With Immune Checkpoint Inhibitors

> **NCT05544149** · PHASE2 · UNKNOWN · sponsor: **Zhejiang Cancer Hospital** · enrollment: 42 (estimated)

## Conditions studied

- SCLC,Extensive Stage

## Interventions

- **RADIATION:** Thoracic radiotherapy

## Key facts

- **NCT ID:** NCT05544149
- **Lead sponsor:** Zhejiang Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-09-01
- **Primary completion:** 2024-08-30
- **Final completion:** 2025-08-30
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2022-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05544149

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05544149, "TRT for ES-SCLC After First Line Treatment With Immune Checkpoint Inhibitors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05544149. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*